Norwegian version of this page

Diseases of esophagus and stomach

The group consists of surgeons, oncologists, a gastroenterologist and pathologist and works for optimization of treatment.

About the group

Purpose of the group is optimalisation of

  • Oncologic and surgical treatment of patients with esophageal cancer and gastric cancer with focus on morbidity, complications and quality of life. 
  • Treatment of patients with benign esophageal diseases (perforations, achalasia, diverticula)
  • Treatment of hiatal hernias and incisional hernias

These goals can be facilitated by participating in studies. A focus will also be translational research aiming at identifying sensitive biomarkers for early detection of cancer.

Projects and Research

  • Continual monitoring of complications and survival (quality assurance) following resection for esophageal- and gastric cancer
  • Continuous biobanking of blood samples and tumor tissue from esophageal cancer and gastric cancer since 2013 for research purposes.  Analyses of biobank material have been ongoing since 2019.
  • A PhD study on local treatment of dysplasia and early cancer as well as hybrid and total minimally invasive resection for stage I-III esophageal cancer is ongoing. 
  • A pilot project on to studying microcirculatory changes in the gastric tube before, under and after surgery for esophageal cancer has been completed. Results are planned for publication.
  • NeoRes II, Scandinavian multicenter randomized study  evaluating effect of awaiting surgery after chemoradiotherapy (CROSS regimen) for 4-6 versus 10-12 weeks is terminated and some results have been published. 
  • The INNOVATION study. European randomised multicenter study, in which patients with HER-2 positive gastric cancer were randomized in three arms for i) chemotherapy, ii) chemotherapy with trastuzumab or iii) chemotherapy with trastuzumab+pertuzumab. End point is overall survival.  EORTC study. Inclusion is still ongoing. 
  • INTENSE study.  Effect of perioperative use of chemotherapy with 4 cycles of FOLFIXFLIRI x 2 in patients with resectable gastric and gastroesophageal junction adenocarcinoma.  Ongoing inclusion.
  • The INEC study is a phase I/II studie run from Oslo University Hospital, where a combination of check-point PD-1 inhibitor (Nivolumab) and different oncologic treatments (palliative radiation/definitive CRT/neoadjuvant CRT) against the esophageal tumor are compared.
  • In the VESTIGE study inclusion in Norway started in January 2020, of patients with high risk for recurrence after surgery with N+ or R1 resection. These patients will receive adjuvant chemotherapy or ipilimumab for 1 year + nivolumab for 1 year.
  • NEEDS study. Neoadjuvant chemoradiotherapy for esophageal  squamous cell carcinoma versus definitive chemoradiotherapy with salvage surgery as needed. Planned to start primo 2021.
  • The group is involved in research on neuroendocrine carcinomas (NEC).
     

Cooperation

Internal

  • Truls Hauge and colleagues at Gastromedical Dep.,OUS,Ullevål
  • Geir Olav Hjortland and colleagues at the Oncological department,OUS,Ullevål
  • Guro Elisabeth Lind and colleagues at Dep. of Molecular Oncology, Institute of Cancer Reseach, OUS,DNR  

International

  • Magnus Nilsson and colleagues at the Gastrosurgical dep., Karolinska University Hospital, Sweden

Selected Publications

  • Gharagozlian S, Mala T, Brekke HK, Kolbjørnsen LC, Ullerud ÅA, Johnson E. Nutritional status, sarcopenia, gastrointestinal symptoms and quality of life after gastrectomy for cancer - A cross-sectional pilot study.Clin Nutr ESPEN. 2020 Jun;37:195-201. doi: 10.1016/j.clnesp.2020.03.001. Epub 2020 Mar 14. PMID:32359743
  • Hauge T, Amdal CD, Falk RS, Johannessen HO, Johnson E. Long-term outcome in patients operated with hybrid esophagectomy for esophageal cancer - a cohort study. Acta Oncol. 2020 Apr 23:1-7. doi: 10.1080/0284186X.2020.1750694. [Epub ahead of print] PMID:32324079 
  • Hauge T, Franco-Lie I, Løberg EM, Hauge T, Johnson E. Outcome after endoscopic treatment for dysplasia and superficial esophageal cancer – a cohort study. Scand J Gastroenterol 2020; DOI 10.1080/00365521.2020.180813
  • Hetland G, Johnson E, Bernardshaw SV, Grinde B. Can medical mushrooms have prophylactic or therapeutic effect aginst COVID-19 and its pneumonic superinfection and complicating inflammation. Review. Scand J Immunol. 2020;00:e12937. doi: 10.1111/sji. 12937.
  • Claassen YHM, Bastiannet E, Hartgrink HH, Dikken JL, de Steur WO, Slingerland M, Verhoeven RHA, van Eycken E, de Shutter H, Lindblad M, Hedberg J, Johnson E, Hjortland  GO, Jensen LS, Larsson HJ, Koessler T, Chevallay M, Allum WH, vand de Velde CJH. International comparison of treatment strategy and survival in metastatic gastric cancer. BJS Open. 2019;3:56-61.
  • Hauge T, Kleven OC, Johnson E, Hofstad B, Johannessen HO. Outcome after iatrogenic esophageal perforation. Scand J Gastroenterol. 2019 Feb;54(2):140-144.
  • Mala T, Johannessen HO, Førland D, Jacobsen TH, Johnson E. Laparoscopic resection for  gastric cancer at Oslo University Hospital, Ullevål 2015-18. Tidsskr Nor Laegeforen. 2018 Nov 5; 138 (18). Doi:10.4045/tidsskr. 18.0404.
  • Hauge T, Kleven OC, Johnson E, Hofstad B, Johannessen HO. Outcome after stenting and débridement for spontaneous esophageal rupture. Scand J Gastroenterol 2018;53(4):398-402.
  • Claassen YHM, Dikken JL, Hartgrink HH, de Steur WO, Slingerland M, Verhoeven RHA, van Eycken E, de Schutter H, Johansson J, Rouvelas I, Johnson E, Hjortland GO, Jensen LS, Larsson HJ, Allum WH, Portielje JEA, Bastiaannet E, van de Velde CJH. North European comparison of treatment strategy and survival in older patients with resectable gastric cancer: A EURECCA upper gastrointestinal group analysis. Eur J Surg Oncol. 2018;44(12):1982-1989.
  • Hauge T, Kleven OC, Johnson E, Hofstad B, Johannessen HO. Outcome food bolus induced esophageal perforation.  Scand J Gastroenterol 2018;53(8):905-909.
  • Amdal CD, Jacobsen AB, Falk RS, Johnson E, OS SS, Warloe T, Bjordal K. Improved treatment decisions in patients with esophageal cancer. Acta Oncol 2017;56(10):1286-1294.
  • Galleberg RB, Knigge U, Tiensu JE, Vestermark LW, Haugvik SP, Ladekarl M, Langer SW, Grønbæk H,  Österlund P, Hjortland GO, Assmus J, Tang L, Perren A. Sorbye H. Results after surgical treatment in  patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. Eur J Surg Oncol  2017; 43 (9):1682-89. 
  • Ali AS, Grönberg M, Federspiel B, Scoazec JY, Hjortland GO, Grønbæk H, Ladekarl M, Langer S, Welin S, Vestermark LW, Österlund P, Knigge U, Sorbye H, Grimelius L, Janson ET. “Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma (WHO G3)”. PLoS  One 12(11):e0187667, Nov7 2017. 
  • Li Y, Li X, Kan Q, Zhang M, Li X, Xu R, Wang J, Goscinski MA, Wen JG, Nesland JM, Suo Z. mitochondrial pyruvate carrier function is negatively linked to Warburg phenotype in vitro and malignant features in esophageal squamous cell carcinomas. Oncotarget 2017;8(1):1058-73.
     

 

Published Aug. 10, 2018 10:33 AM - Last modified Oct. 1, 2020 10:06 AM

Contact

Group Leader

Participants

  • Egil Johnson
  • Else Marit Løberg
  • Al-Haidari Ghazwan
  • Brit Dybdahl
  • Caroloine Ursin skagemo
  • Dag T. Førland
  • Geir Olav Hjortland
  • Hans-Olaf Johannessen
  • Jorunn Skattum
  • Tobias Hauge
  • Torgeir Thorson Søvik
Detailed list of participants